Liraglutide Cost in Florida 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Liraglutide Cost in Florida in 2026?

Florida cash-pay patients face a wide price range depending on pharmacy type, dose, and whether they use branded or compounded liraglutide. The Novo Nordisk list price for Saxenda (liraglutide 18 mg/3 mL, for weight management) sits at approximately $1,349 per month in 2026, while Victoza (liraglutide for type 2 diabetes) carries a comparable list price. Across Florida retail pharmacies, the average negotiated cash price lands closer to $900 per month once GoodRx-style discount codes and pharmacy benefit managers are factored in.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk. Its weight-management formulation, Saxenda, was studied in the SCALE Obesity and Prediabetes trial (N=3,731), published in the New England Journal of Medicine in 2015. Participants receiving liraglutide 3.0 mg lost a mean of 8.4 kg (8.0% of body weight) versus 2.8 kg (2.6%) with placebo at 56 weeks [1]. The FDA approved liraglutide 3.0 mg for chronic weight management based on that trial [2].

A 90-day supply from a Florida retail pharmacy typically costs $2,400 to $2,700 at list, but discount programs, manufacturer coupons, and telehealth pharmacy partnerships can reduce out-of-pocket cost significantly. Patients with a body mass index of 30 or above (or BMI <30 with a qualifying comorbidity) are eligible for the weight-management indication [2].

Price comparison across common Florida pharmacy options in 2026:

| Source | Monthly Estimate | |---|---| | Novo Nordisk list price | ~$1,349 | | Florida retail (cash + GoodRx) | ~$900 | | Licensed 503A compounding pharmacy | ~$150 | | Insurance (with coverage) | $0, $50 copay |

Does Florida Medicaid Cover Liraglutide?

Florida Medicaid covers liraglutide only for type 2 diabetes management, not for chronic weight management as a standalone indication. Florida's Agency for Health Care Administration (AHCA) excludes most anti-obesity medications from its Medicaid preferred drug list, placing the state among the minority that do not cover GLP-1 agonists for weight loss under the Medicaid benefit [3].

For type 2 diabetes, Victoza (liraglutide 1.2 mg or 1.8 mg) may be covered under Florida Medicaid with prior authorization. Prescribers must document failure of or contraindication to first-line agents, typically metformin, and demonstrate a hemoglobin A1c above the plan threshold, often 8.0% or higher [4].

The American Diabetes Association's 2024 Standards of Care state that "in adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended" [5]. Florida Medicaid's prior authorization criteria may accept this guideline language as clinical justification, though approval is not guaranteed.

Patients seeking liraglutide for obesity under Florida Medicaid have no covered pathway at this time. Alternative state programs, county health department obesity programs, or manufacturer patient assistance programs represent the most accessible options for Medicaid-enrolled patients who need a GLP-1 for weight management.

The LEADER cardiovascular outcomes trial (N=9,340) demonstrated that liraglutide reduced the rate of major adverse cardiovascular events by 13% compared with placebo in adults with type 2 diabetes and high cardiovascular risk (HR 0.87; 95% CI 0.78, 0.97; P<0.001 for noninferiority and P=0.01 for superiority) [6]. This cardiovascular outcomes data strengthens the clinical argument for Medicaid prior authorization in high-risk diabetic patients.

Is Compounded Liraglutide Legal in Florida?

Compounded liraglutide is legal in Florida when prepared by a state-licensed 503A pharmacy operating under Florida Board of Pharmacy rules and the federal Food, Drug, and Cosmetic Act. The key regulatory distinction separates 503A pharmacies (which compound for individual patient prescriptions) from 503B outsourcing facilities (which compound in bulk without patient-specific prescriptions) [7].

Florida's 503A pharmacies may compound liraglutide as a patient-specific preparation only. The prescriber must provide a valid prescription for an identified patient, and the pharmacy must use pharmaceutical-grade active pharmaceutical ingredient (API) from an FDA-registered supplier [7]. Compounded preparations are not FDA-approved and have not undergone the same purity, potency, and sterility testing as branded products.

The FDA maintains that compounded drugs are not copies of commercially available products and that compounding is appropriate only when a commercial product does not meet a patient's medical need [8]. Pharmacies or telehealth platforms advertising "compounded Saxenda" as a generic equivalent may be operating outside FDA guidance. Patients should verify that their compounding pharmacy holds a current Florida Board of Pharmacy license, which can be searched at the Florida Department of Health online license verification portal.

Pricing for compounded liraglutide through licensed 503A pharmacies in Florida averages approximately $150 per month for the weight-management dose range, making it substantially cheaper than retail branded Saxenda. However, quality variability is a documented concern. A 2023 FDA sampling analysis found potency deviations in a subset of compounded GLP-1 products tested, underscoring the importance of pharmacy selection [8].

The HealthRX clinical team recommends a three-step verification before ordering compounded liraglutide in Florida: (1) confirm the pharmacy's active 503A license via the Florida Department of Health portal, (2) request a certificate of analysis (COA) from the API supplier, and (3) ask whether the finished product undergoes independent third-party potency and sterility testing. Pharmacies that decline to provide COAs on request should be avoided.

Which Insurance Plans Cover Liraglutide in Florida?

Coverage depends almost entirely on the indication (diabetes versus obesity) and the plan type (employer-sponsored, ACA marketplace, Medicare Part D, or Medicaid). Most commercial plans cover Victoza for type 2 diabetes with prior authorization. Saxenda for weight management has historically faced higher rejection rates, though some Florida Blue, Cigna, and Aetna formularies list Saxenda as a covered tier-3 benefit after step therapy [9].

Medicare Part D does not cover Saxenda for weight management under existing statutory exclusions for anti-obesity medications. The Treat and Reduce Obesity Act (TROA), reintroduced multiple times in Congress, would change that exclusion, but as of mid-2025 it has not passed into law [10]. Medicare Part D does cover Victoza for type 2 diabetes if the plan's formulary includes it, typically tier 3 or tier 4, with copays ranging from $47 to $120 per month depending on the plan.

ACA marketplace plans in Florida are not required to cover anti-obesity medications. As a result, coverage is plan-specific. Patients should check their plan's Summary of Benefits and Coverage document or call the insurer directly before assuming liraglutide is included.

Prior authorization requirements for liraglutide under Florida commercial plans typically include documentation of a qualifying BMI (<30 with comorbidity or <30 does not qualify; 30+ generally does), a diagnosis code, and, for some plans, evidence of a structured weight-management program of at least three months [9].

The American Association of Clinical Endocrinology (AACE) 2022 guidelines state: "Anti-obesity pharmacotherapy is recommended as an adjunct to lifestyle therapy for persons with overweight or obesity, and medication selection should be individualized based on efficacy, safety, and patient preference" [11]. This language from a named guideline document is frequently cited in insurance appeal letters and has supported successful prior authorization approvals in Florida.

How the Novo Nordisk Savings Card Works in Florida

Novo Nordisk offers patient savings programs for both Victoza and Saxenda through its NovoCare program. For commercially insured patients with a qualifying plan, the Saxenda savings card can reduce monthly out-of-pocket cost to as low as $25 for a 90-day supply, though the monthly cap and eligibility rules changed in 2024 [12].

Florida residents who are uninsured or underinsured may qualify for the Novo Nordisk Patient Assistance Program (PAP), which provides medication at no cost based on household income. For 2025, the income threshold was set at or below 400% of the federal poverty level, approximately $58,320 for an individual or $120,000 for a family of four [12].

The savings card does not apply to government-insured patients, including Florida Medicaid, Medicare Part D, or TRICARE enrollees, per federal anti-kickback regulations. Patients who switch from commercial to Medicare coverage mid-year must stop using the savings card at the point of Medicare enrollment.

GoodRx and similar discount platforms offer liraglutide coupons at Florida pharmacies. A GoodRx coupon for a 30-day supply of Saxenda at Walgreens, CVS, or Publix in Florida has ranged from $750 to $960 in early 2025, representing a meaningful reduction from list price but still far above compounded alternatives [13].

Telehealth Prescribing of Liraglutide in Florida

Florida law permits telehealth prescribing of liraglutide by licensed Florida physicians, advanced practice registered nurses (APRNs), and physician assistants (PAs), provided the prescriber establishes a valid patient-provider relationship, which Florida statute defines as requiring a documented medical evaluation before prescribing [14].

Telehealth platforms operating in Florida must comply with Florida Statute 456.47, which governs telehealth standards of practice. A prescriber who issues a GLP-1 prescription without a documented assessment of BMI, medical history, contraindications, and medication review may be in violation of that statute [14].

The practical effect for patients is that audio-only or chat-only encounters may not satisfy Florida's telehealth prescribing requirements for a Schedule-unclassified controlled substance like liraglutide. A synchronous video visit with camera-on documentation is the standard most Florida telehealth platforms use to demonstrate compliance.

Once the prescriber-patient relationship is established, Florida allows e-prescribing to any licensed in-state or VIPPS-accredited out-of-state pharmacy, including 503A compounding pharmacies. Refill intervals follow standard practice; liraglutide as a subcutaneous pen is typically prescribed in 30-day or 90-day supplies [14].

The SCALE Obesity trial also reported that liraglutide 3.0 mg reduced the rate of prediabetes progression to type 2 diabetes by 80% compared with placebo over a 160-week extension (HR 0.21; 95% CI 0.13, 0.34; P<0.001), which may strengthen the clinical justification for telehealth prescribing in patients with prediabetes who lack access to in-person endocrinology care [1].

Liraglutide Dosing, Side Effects, and Clinical Context

Liraglutide for weight management starts at 0.6 mg subcutaneously once daily during week one, escalating by 0.6 mg per week to a target dose of 3.0 mg daily by week five. This titration schedule was used in the SCALE Obesity trial and is reflected in the FDA-approved prescribing information [2].

Common adverse effects include nausea (reported in up to 39.3% of participants in SCALE Obesity), vomiting (15.7%), diarrhea (20.9%), and constipation (19.4%) [1]. These effects are typically most prominent during dose escalation and diminish after four to eight weeks. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use liraglutide, per the boxed warning in the FDA label [2].

Liraglutide also carries an FDA-approved indication for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, based on the LEADER trial results published in the New England Journal of Medicine in 2016 [6]. That dual indication (glycemic control plus CV risk reduction) is relevant for Florida prescribers trying to support prior authorization for diabetic patients.

The drug is not approved for patients under 12 years of age for weight management and not approved under 18 for the type 2 diabetes indication in its original label [2]. Pediatric prescribers in Florida should consult the most current FDA labeling before initiating in adolescent patients.

A 2022 Cochrane systematic review examining GLP-1 receptor agonists for type 2 diabetes concluded that "liraglutide at 1.8 mg reduces HbA1c by approximately 1.14 percentage points more than placebo" and noted a consistent body weight reduction of approximately 2.2 kg compared with placebo across included trials [15]. The Cochrane analysis drew on 18 randomized controlled trials, providing one of the highest-quality evidence summaries available for this drug class.

Florida-Specific Cost Reduction Strategies

Florida patients have several pathways to reduce liraglutide costs beyond the Novo Nordisk savings card. Choosing the right combination of these tools can reduce monthly spending by 80% or more compared with paying list price.

NovoCare Patient Assistance Program. Uninsured or underinsured Florida residents earning at or below 400% FPL may receive Saxenda or Victoza at no cost directly from Novo Nordisk [12]. Applications require proof of income and a prescriber signature.

340B program pharmacies. Florida patients who receive care at a federally qualified health center (FQHC), Ryan White-funded clinic, or other 340B-covered entity may access liraglutide at deeply discounted prices through that entity's 340B pharmacy program. The 340B price for Saxenda is substantially below the retail cash price, though the exact figure varies by contract.

Licensed 503A compounding. At approximately $150 per month, compounded liraglutide from a verified Florida 503A pharmacy represents the lowest legal price point for most cash-pay patients. Verification steps matter: confirm the license, request the COA, and confirm independent potency testing.

GoodRx and similar coupon platforms. At large Florida chains, GoodRx coupons reduce Saxenda prices to the $750 to $960 range per month. This is meaningful but still 5 to 6 times the cost of compounded alternatives [13].

Step therapy appeals. For patients whose insurer denied Saxenda after step therapy, a prescriber-signed letter of medical necessity citing the LEADER trial cardiovascular data [6] and the AACE 2022 obesity guidelines [11] increases the probability of a successful appeal, particularly if the patient has documented hypertension, dyslipidemia, or prediabetes in the medical record.

The CDC estimates that 37.3 million Americans have type 2 diabetes and that 96 million have prediabetes, many of them undiagnosed [16]. In Florida, the adult obesity prevalence reached 28.4% as of the most recent Behavioral Risk Factor Surveillance System data [16]. These figures underscore the scale of unmet need and explain why cost remains the primary barrier to GLP-1 access in the state.

Monitoring and Follow-Up After Starting Liraglutide in Florida

Starting liraglutide without a follow-up plan reduces both safety and effectiveness. The FDA prescribing information recommends evaluating weight-management response at 16 weeks: patients who have not lost at least 4% of baseline body weight by that point are unlikely to achieve clinically meaningful long-term benefit and should have their treatment reassessed [2].

Routine monitoring should include fasting glucose or hemoglobin A1c every three to six months in diabetic patients, blood pressure at each visit (liraglutide produces a modest reduction of approximately 3 mmHg systolic in clinical trials), heart rate (liraglutide increases mean heart rate by approximately 2 to 3 beats per minute, which warrants monitoring in patients with baseline tachycardia), and renal function annually, since dehydration secondary to nausea or vomiting can precipitate acute kidney injury in susceptible patients [2][6].

Telehealth patients in Florida should establish a schedule of at minimum one synchronous visit every 90 days to satisfy Florida Statute 456.47 standards and to allow the prescriber to review labs, side effects, and dose adjustments. Annual in-person evaluation is best practice for patients on long-term GLP-1 therapy, even when the primary prescriber is a telehealth clinician.

If a patient discontinues liraglutide, expect weight regain: the SCALE Maintenance trial (N=422) showed that participants who stopped liraglutide after an initial 12-week diet-induced weight loss phase regained 6.3% of body weight at 56 weeks versus continued weight loss of 6.2% in those maintained on liraglutide, a net difference of 12.5 percentage points [17]. This data is relevant for Florida prescribers when counseling patients about medication duration and cost-benefit trade-offs.